Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.71
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
IBBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (9)
- News (RSS)fool·1d ago·Neutral
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.
View source ↗ - News247wallst.com·5d ago·Negative
Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked A 100% tariff on imported drugs just expanded to cover every drugmaker in the country, yet the biotech market's most closely watched fund treated it like a non-event. The reason says everything about who actually pays.
View source ↗ - News (RSS)fool·10d ago·Positive
Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.
View source ↗ - Newsfool.com·10d ago·Neutral
Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK The iShares Biotechnology ETF carries a lower expense ratio and significantly larger assets under management (AUM) than the Simplify Health Care ETF. The Simplify Health Care ETF provides broader exposure across healthcare sub-sectors and a higher dividend yield than the biotechnology-focused iShares fund.
View source ↗ - Newsdefenseworld.net·11d ago·Negative
104,009 iShares Biotechnology ETF $IBB Shares Sold by Envestnet Asset Management Inc. Envestnet Asset Management Inc. decreased its stake in iShares Biotechnology ETF (NASDAQ: IBB) by 8.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,122,659 shares of the financial services provider's stock after selling 104,009 shares during
View source ↗ - News (RSS)fool·11d ago·Neutral
XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.
View source ↗ - News247wallst.com·28d ago·Neutral
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party? Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy
View source ↗ - Newszacks.com·36d ago·Positive
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
View source ↗ - Newsbenzinga.com·46d ago·Neutral
Biotech Is Booming, But These 2 Stocks Missed the Memo Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDAQ:IBB) jumped nearly 5% Wednesday and pushed to new all-time highs, according to data from Benzinga Pro.
View source ↗
Congress trades
- David Joycehouse · OH14 · disclosed May 8, 2019 (804d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.